• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1246197 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type5 O! e# v) [! y7 v+ k+ Q
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
: n/ A+ @# ~! I4 G3 h, Y+ Author Affiliations  o' L+ W% ]( s2 b6 e+ M
0 P6 ^1 f' A4 [1 y9 `" l; \7 }
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan   @9 O2 T1 `$ t1 T* Y" K
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 1 N# {- E$ P$ ~
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan & i4 A. O' N6 H8 j
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
4 F# _8 F- I" S: ~5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan / z  }2 m0 Z+ ~0 {! k$ Y
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan - K( ^6 S  |- h+ n& _4 K
7Kinki University School of Medicine, Osaka 589-8511, Japan ( ^  `: f' [0 L6 L* e1 H* p' ~% S
8Izumi Municipal Hospital, Osaka 594-0071, Japan
( S$ p8 A7 Q$ x0 t7 G9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
: d8 b* f" I* PCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; t2 Z, B# C8 _/ A: v9 ^9 {
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
. j4 s- x" V: _# Q' y& x& j
( t7 y7 _$ }# u+ D- x# B' p
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
- E; u' C: N  ^6 I" O" m; q7 Z: N- n- p. ]
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
8 @- V: s" d! C
  ^- R( [! [5 M) O" ^, HAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
, ^) F* I2 K) r# M# T
4 V% t  y  c4 v  ]# `) sPublished online on: Thursday, December 1, 2011 % x; c+ D( g8 Y* X" r
- k% G( [7 o: h0 ~- H2 c; y
Doi: 10.3892/ol.2011.507 0 i; J0 B- _( Z& }- f# }1 a

0 _+ v+ E* z0 S1 T4 p6 n8 bPages: 405-410
3 r0 z0 {" r8 X% z* E. O- d& N* T6 d8 k6 k8 k
Abstract:( r8 ~. ^0 x1 N; e! b
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
1 j& X4 g; d, V
4 A' f# Z- W6 s2 T# u
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population; V  C- r4 ^$ `" e& C: K* }
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
- L6 Q' T3 Y! r( v6 p4 z/ o0 `+ Author Affiliations
! L8 _, l) O0 O2 y! I" X* c" @! k1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu ! e/ N$ g# a8 j$ \# n  s9 ?
2Department of Thoracic Surgery, Kyoto University, Kyoto ! s2 _1 B' P5 s4 `+ U
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan ( [  l9 y$ I9 R3 z5 m$ P
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp $ e1 n! S: _4 P  c  I+ y
Received September 3, 2010.
: S' c+ o. ?/ ~. M9 ^8 CRevision received November 11, 2010.
" L$ Q9 T, d, K) r3 l  \Accepted November 17, 2010. , `2 Q" ]* t: I  ^+ V1 Y
Abstract0 V6 I7 v" k, T! J1 H4 l
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. " `) O8 c: r6 w* X
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
! o8 z* F( I! H7 E  c- a2 pResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. + [- L6 z7 q/ w
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
' b% ^3 c3 F4 D% j" B
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。; T' L9 D( n1 k% q5 J& X+ `
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
$ m7 T# F6 f! x1 E( h" v$ m2 G
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy) p/ F- h; B8 p+ n) S# C: ?
http://clinicaltrials.gov/ct2/show/NCT01523587$ V- l- F, G2 I# ?2 L

  h9 b5 w/ W1 T# A+ f; }/ @BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC- u: [/ j. ^0 D7 V+ d3 u  O
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 * Y- Y2 w" p  z! p: k
4 y+ @4 f! |4 c; I% _: |( L) ]
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
) m, f6 Q# I1 F5 f/ b$ s, Y) s( u至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
  _7 }4 O( y7 R+ H4 X- {7 ~从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。" \' a8 c% p  A2 t
至今为止,未出 ...
) w( _6 }. Z4 M: g. i
没有副作用是第一追求,效果显著是第二追求。
' c# C. u+ l; P2 ]: p; e不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表